Value-Based Healthcare Model of Medical and Pharmaceutical Care for Patients With Coronary Artery Disease with Comorbid Conditions: Cost- Benefit Analysis in the Healthcare Setting of Ukraine
This study proposes and validates a value-based, three-level pharmaceutical care model for Ukrainian patients with coronary artery disease and comorbidities, demonstrating through cost-benefit analysis that integrating clinical pharmacists and original fixed-dose combinations significantly reduces cardiovascular events and generates substantial net economic benefits across multiple healthcare perspectives.